Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity

BACKGROUND: Several agents for oncolytic immunotherapy have been approved for clinical use, but monotherapy is modest for most oncolytic agents. The combination of several therapeutic strategies through recombinant and nanotechnology to engineer multifunctional oncolytic viruses for oncolytic immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jin-Yan, Chen, Hengyu, Dai, Shu-Zhen, Huang, Feng-Ying, Lin, Ying-Ying, Wang, Cai-Chun, Li, Lei, Zheng, Wu-Ping, Tan, Guang-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905871/
https://www.ncbi.nlm.nih.gov/pubmed/35256516
http://dx.doi.org/10.1136/jitc-2021-003950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905871/
https://www.ncbi.nlm.nih.gov/pubmed/35256516
http://dx.doi.org/10.1136/jitc-2021-003950

Ejemplares similares